<DOC>
	<DOC>NCT01870401</DOC>
	<brief_summary>To assess the safety and efficacy of the Lutonix Drug Coated Balloon (DCB) for treatment of stenosis or occlusion of native below-the-knee arteries.</brief_summary>
	<brief_title>Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<criteria>Male or nonpregnant female ≥18 years of age; Rutherford Clinical Category 3, 4 &amp; 5; Life expectancy ≥ 1 year; Significant stenosis (≥70%) A patent inflow artery; Target vessel(s) diameter between 2 and 4 mm; Target vessel(s) reconstitute(s) at or above the ankle Pregnant or planning on becoming pregnant; History of stroke within 3 months; History of MI, thrombolysis or angina within 30 days of enrollment; Planned major amputation (of either leg) Prior major amputation if amputation occurred less than one year prior to enrollment and if patient is not independently ambulating; GFR ≤ 30 ml/min per 1.73m2; Acute limb ischemia; Instent restenosis of target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>